---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-25-010510"
form_type: "8-K"
ticker: "TENX"
cik: "0000034956"
company_name: "TENAX THERAPEUTICS, INC."
filed_at: "2025-09-09T23:59:59+00:00"
generated_at: "2026-05-17T07:24:35.398694+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Tenax Therapeutics expands levosimendan license to exclusive worldwide oral rights; gains manufacturing rights

## Summary
- Amendment with Orion grants Tenax exclusive worldwide rights to develop, commercialize, and manufacture oral levosimendan products.
- Tenax also obtains manufacturing rights for subcutaneously administered levosimendan products under the expanded license.
- Orion will supply levosimendan API at low triple-digit thousand Euros/kg, minimum order [***] grams, payment within 45 days.
- Fifth Amendment builds on prior agreements; effective September 3, 2025.

## SEC filing metadata
- accession: 0001654954-25-010510
- form_type: 8-K
- ticker: TENX
- cik: 0000034956
- company_name: TENAX THERAPEUTICS, INC.
- filed_at: 2025-09-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/34956/000165495425010510/0001654954-25-010510-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/34956/000165495425010510/tennx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-25-010510
- JSON: https://secwatch.observer/filing/0001654954-25-010510.json
- Plain text: https://secwatch.observer/filing/0001654954-25-010510.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.